TEARSOLUTIONS
TearSolutions is a pharmaceutical company that specializes in providing medical solutions for dry eyes. The company is driven by its mission is to develop a novel replacement therapy for dry eye through phase II human clinical trials. The platform technology is centered on the remarkable tear protein and the proprietary drug 'Lacripep'. An outsourcing model will be used.
TEARSOLUTIONS
Industry:
Eyewear Medical Pharmaceutical
Founded:
2013-01-01
Address:
Charlottesville, Virginia, United States
Country:
United States
Website Url:
http://www.tearsolutions.com
Total Employee:
1+
Status:
Active
Contact:
4349823912
Total Funding:
21.12 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Scilex Pharmaceuticals
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Gordon W. Laurie Co-Founder & CSO @ TearSolutions
Co-Founder & CSO
Mark B. Logan Co-Founder , President & CEO @ TearSolutions
Co-Founder , President & CEO
Founder
Investors List
Pharmstandard
Pharmstandard investment in Series B - TearSolutions
Virginia Tech Carilion (VTC) Innovation Fund
Virginia Tech Carilion (VTC) Innovation Fund investment in Series B - TearSolutions
Virginia Tech Carilion (VTC) Innovation Fund
Virginia Tech Carilion (VTC) Innovation Fund investment in Series B - TearSolutions
Pharmstandard
Pharmstandard investment in Series B - TearSolutions
UVA Licensing & Ventures Group
UVA Licensing & Ventures Group investment in Venture Round - TearSolutions
Medarva Innovations
Medarva Innovations investment in Series A - TearSolutions
LaunchCapital
LaunchCapital investment in Series A - TearSolutions
Santen Pharmaceutical
Santen Pharmaceutical investment in Series A - TearSolutions
Center for Innovative Technology
Center for Innovative Technology investment in Series A - TearSolutions
Official Site Inspections
http://www.tearsolutions.com
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "TearSolutions"
TearSolutions - Crunchbase Company Profile & Funding
TearSolutions is a pharmaceutical company that specializes in providing medical solutions for dry eyes. The company is driven by its mission is to develop a …See details»
TearSolutions Inc. - LinkedIn
TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for …See details»
TearSolutions - Overview, News & Similar companies - ZoomInfo
TearSolutions Expands and Establishes Advisory Boards and Strengthens Leadership Team CHARLOTTESVILLE, Va., March 07, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc. a …See details»
Tearsolutions, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tearsolutions, Inc. of Charlottesville, VA. Get the latest business insights from Dun & Bradstreet.See details»
TearSolutions 2025 Company Profile: Valuation, Funding
TearSolutions was founded in 2013. Where is TearSolutions headquartered? TearSolutions is headquartered in Charlottesville, VA. What is the size of TearSolutions? TearSolutions has 10 …See details»
TearSolutions Company Information - Funding, Investors, and More
TearSolutions Inc. is a Delaware Corporation based in Charlottesville, VA. The company has successfully completed a well-powered 204 patient Phase II Proof of Concept clinical trial for …See details»
TearSolutions - Contacts, Employees, Board Members, Advisors
TearSolutions is a pharmaceutical company that specializes in providing medical solutions for dry eyes. New. Resources. Advanced Search ... Log In. Log In. Experience the new Crunchbase, …See details»
TearSolutions - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
TearSolutions, Inc. (TearSolutions, Inc.) - 药物管线_专利_临床试验_ …
Dr. Alpern brings extensive clinical trialing experience in ophthalmologyCHARLOTTESVILLE, Va., April 03, 2024 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company …See details»
TearSolutions • UVA Licensing & Ventures Group - University of …
TearSolutions has developed ‘Lacripep’, which is derived from Lacritin protein as a first-in-class topical therapy that preserves all of Lacritin’s bioactivity. Preclinical data showed that, when …See details»
Tearsolutions Inc. Company Information - Funding, Investors, and …
Key Insights: Tearsolutions Inc. Funding Round, January 2022: $7m Tearsolutions Inc. Funding Round, February 2020: $1.5m Tearsolutions Inc. Funding Round, March 2019 ...See details»
TearSolutions Company Profile - Craft
TearSolutions has 5 employees at their 1 location and $19.79 m in total funding,. See insights on TearSolutions including office locations, competitors, revenue, financials, executives, …See details»
TearSolutions, Inc. Secures $3M Series B Funding
November 21, 2024, Charlottesville, VA – TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface related diseases, …See details»
TearSolutions, Inc., Announces Results From First-In-Human …
TearSolutions is a privately held biotechnology company focused on the discovery, development and commercialization of novel therapies for the treatment of patients with DED. The …See details»
TearSolutions Inc. | Charlottesville VA - Facebook
Nov 21, 2024 TODAY! As part of ARVO 2024 activities, TearSolutions Inc. TearSolutions Inc. has been invited to present at DryHorizons hosted by Ora and OIS. Anil Asrani, CEO of …See details»
TearSolutions - CvilleBioHub
Oct 7, 2020 TearSolutions is focused on dry eye, the most common eye disease. The mission of TearSolutions is to advance a novel tear generation therapy for dry eye through Phase II …See details»
TearSolutions Raises $3M Series A Round to Advance The …
Nov 4, 2015 TearSolutions is a development-stage biotechnology company that is advancing a novel, first-in-class topical treatment for dry eye through phase I/II human clinical trials for exit. …See details»
TearSolutions - Raised $43.6M Funding from 7 investors - Tracxn
Mar 21, 2025 TearSolutions has raised a total funding of $43.6M over 11 rounds from 7 investors. Investors include LaunchCapital, Santen Pharmaceuticals and 5 others. Their latest …See details»
TearSolutions, Inc. Secures $3M Series B Funding - GlobeNewswire
Nov 21, 2024 TearSolutions is a privately held biotechnology company focused on the discovery, development and commercialization of novel therapies for the treatment of patients …See details»